Results 211 to 220 of about 10,001 (276)

Defining Renal Recovery in Patients With Hepatorenal Syndrome-Acute Kidney Injury: Experience From North American Studies. [PDF]

JGH Open
Mujtaba MA, Elsiesy H, Faiz S, Hussain SA, Gamilla-Crudo AKN, Karim A, Khan MI, Khattak MW, Zafar Z, Kueht M, Jamil K.   +10 more
europepmc   +1 more source

Hepatorenal Syndrome: A Critical Complication in Advanced Cirrhosis. [PDF]

Cureus
Maram Reddy VY, Maramreddy KR.
europepmc   +1 more source

Comparison of short-term and long-term renal function effects of vasopressin and norepinephrine in patients with septic shock: a systematic review and meta-analysis. [PDF]

Front Pharmacol
Wang H, Liu X, Zhang H.
europepmc   +1 more source

Expanding the boundaries of kidney replacement therapy in patients with liver failure. [PDF]

World J Crit Care Med
Belal AA, Santos AH, Koratala A, Kazory A.   +3 more
europepmc   +1 more source

Hepatorenal Syndrome: direct treatment costs and characteristics of patients admitted to intensive care. [PDF]

Einstein (Sao Paulo)
Hortelã FR, Kruger RS, Oliveira VF, Carraro Junior H, Muzzillo DA, Kowalski SC.   +5 more
europepmc   +1 more source

Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome

New England Journal of Medicine, 2021
BACKGROUND The vasoconstrictor terlipressin is used for type 1 hepatorenal syndrome (HRS-1) in many parts of the world and is part of the clinical practice guidelines in Europe. METHODS We conducted a phase 3 trial to confirm the efficacy and safety of
Florence S H Wong, Michael Curry, K Rajender Reddy   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Evaluation of terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury using point-of-care echocardiography

Hepatology, 2023
Background and Aims: Treatment of hepatorenal syndrome-acute kidney injury (HRS-AKI), with terlipressin and albumin, provides survival benefits, but may be associated with cardiopulmonary complications. We analyzed the predictors of terlipressin response
M. Premkumar, Kamal Kajal, K. Reddy, M. Izzy, Anand V. Kulkarni, A. Duseja, K. B. Sihag, S. Divyaveer, Ankur Gupta, S. Taneja, Arka De, N. Verma, S. Rathi, H. Bhujade, Sreedhara B. Chaluvashetty, Akash Roy, Vishesh Kumar, Vuppada Siddhartha, Virendra Singh, Ajay Bahl   +19 more
semanticscholar   +1 more source

Comparison of 1‐day versus 3‐day intravenous terlipressin in cirrhosis patients with variceal bleeding: A pilot randomised controlled trial

Alimentary Pharmacology and Therapeutics
In cirrhosis patients with acute variceal bleeding (AVB), the optimal duration of vasoconstrictor therapy after endoscopic haemostasis is unclear.
M. Vaishnav, S. Biswas, Abhishek Shenoy, P. Pathak, A. Anand, Shekhar Swaroop, Arnav Aggrawal, U. Arora, A. Elhence, Soumya Jagannath, D. Gunjan, S. Kedia, A. K. Mishra, S. Gamanagatti, B. Nayak, Pramod K. Garg, Shalimar   +16 more
semanticscholar   +1 more source

Continuous home terlipressin infusion increases handgrip strength and reduces ascites—A prospective randomized crossover study

Hepatology
Background and Aims: Observational studies suggest a beneficial effect of continuous terlipressin infusion (CTI) on ascites and sarcopenia in decompensated cirrhosis with portal hypertension.
R. Terbah, A. Testro, Rudolf Hoermann, Avik Majumdar, B. Chapman, Paul Gow, M. Sinclair   +6 more
semanticscholar   +1 more source

Decreased need for RRT in liver transplant recipients after pretransplant treatment of hepatorenal syndrome-type 1 with terlipressin

Liver transplantation, 2023
Hepatorenal syndrome-acute kidney injury (HRS-AKI), a serious complication of decompensated cirrhosis, has limited therapeutic options and significant morbidity and mortality.
E. Weinberg, F. Wong, Hugo E. Vargas, Michael P. Curry, K. Jamil, S. C. Pappas, Pratima Sharma, K. R. Reddy   +7 more
semanticscholar   +1 more source